> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Priority Voucher Used on AbbVie’s Skyrizi
- URL: https://www.fdaweb.com/priority-voucher-used-on-abbvies-skyrizi/
- Published: 2022-11-23T12:00:00.000Z
- Updated: 2026-09-14T18:07:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5153257

*Federal Register* notice: FDA has announced that a priority review voucher was redeemed 6/16 by AbbVie for its supplemental BLA for Skyrizi (risankizumab-rzaa) to expand its indication for treating moderately to severely active Crohn’s disease in adults. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-25644.pdf?ref=fdaweb.com).